Pre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
|
|
- Hillary Tucker
- 6 years ago
- Views:
Transcription
1 Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light of the new USPSTF D recommendation I plan to reduce / stop PSA screening in my practice. 3. The USPSTF D recommendation is not strongly evidence-based, and will not change my practice. 4. I am unaware of the USPSTF D recommendation. 42% 42% 11% 5% June 28, Prostate Cancer 2012 The Good News: 40% drop in age-adjusted prostate cancer mortality since early 1990s Siegel et al. CA Cancer J Clin 2012; 62:10 Siegel et al. CA Cancer J Clin 2012; 62:10 1
2 So why did we end up here? This is our fault. Moyer et al. Ann Intern Med, epub Prostate cancer is heterogeneous The Changing Face of Prostate Cancer Esserman et al. JAMA 2009; 302:1685 Cooperberg et al. J Urol 2007; 178:S14 2
3 Risk by Age Natural history of low-risk disease Cooperberg et al. JCO 2009; 27:4306 Lu-Yao et al. JAMA 2009; 302:1202 Natural history of high-risk disease Benefits of Screening: The RCTs Lu-Yao et al. JAMA 2009; 302:1202 3
4 PLCO Prostate, Lung, Cancer, & Ovarian Cancer Screening Trial PLCO 76,693 men aged randomly assigned to annual PSA screening for 6 years vs. usual care at 10 U.S. centers Up to 1995, any prior screening allowed; starting in 1995, no more than 1 PSA within past 3 years 44.1% of control group had had 1 PSA in past 3 years; 53.9% had had 1 DRE PSA >4.0 ng/ml considered abnormal Cancer incidence ascertained by questionnaire Andriole et al. NEJM 2009; 360:1310 Andriole et al. NEJM 2009; 360:1310 PLCO Compliance with screening 85% in screening arm Rate of screening in control arm 40% in first year, 52% in sixth year Rate of biopsy among those with PSA >4 fell from the 40% in study first year was to not 30% a fair by comparison third year [Grubb between al. BJU screening Int 2008; 102:1524] and no screening; instead, it was a comparison At 7 years, prostate between cancer annual diagnosed and ad hoc in screening screening Cooperberg pts and 2322 Carroll, controls, NEJM RR 2009; :203 ( ) 96.0% vs 94.3% of screened vs control tumors were stage I-II; 32% vs 39% were GS 7 At 7 years, 50 cancer-specific deaths in screening group, 44 in control group, RR 1.13 ( ) PLCO: the contamination problem Data from surveys of the control arm of the PLCO study: Andriole et al. NEJM 2009; 360:1310 Pinsky et al. Clin Trials 2010; 7:303 4
5 PLCO: the contamination problem PLCO: Update Given the high level of contamination in PLCO, one way of interpreting the trial is that it is a study of an active (organized) program of screening versus passive (opportunistic) screening, that is, the current level of screening ongoing in the community a finding of no benefit implies that an organized program does not confer significantly greater mortality benefit for prostate cancer than opportunistic screening as currently carried out in the US. However, the study interpreted in this manner would not be able to answer the question of whether that level of opportunistic screening is conveying a mortality benefit over no screening. PLCO was not a trial of screening vs. no screening Pinsky et al. Clin Trials 2010; 7:303 Andriole et al. J Natl Cancer Inst 2012; 104:1 ERSPC European Randomized Study of Screening for Prostate Cancer ERSPC Population-based study at 7 European centers 182,160 men age randomized (162,387 in core age 55-69) In 3 centers, men were randomized from population lists before informed consent; in other 4 they were identified from population lists but randomized after consent Screening interval 4 years at most centers (2 at one) Some variation in thresholds for biopsy (3.0 ng/ml vs 4.0 with ancillary tests (DRE/fPSA/TRUS) for values between 2.5 or 3.0 and 4.0. Schröder et al. NEJM 2009; 360:1320 Schröder et al. NEJM 2009; 360:1320 5
6 ERSPC 82% compliance with screening in screening arm (better in consent-first countries) 85.8% compliance with biopsy recommendations Incidence 4.8% in control, 8.2% in screening arm 27.8% vs 45.2% of screened vs. control tumors were Gleason 7 Adjusted mortality rate ratio 0.8 ( ) in favor of screening. Mortality rates begin diverging at 7 years. Other findings from ERSPC No substantial heterogeneity among different centers in Europe (mortality reduction varies from 16-26%) Absolute mortality risk reduction 7 per 10,000 men screened NNS: 1,410 NNT: 48 in excess of control group at 9 years NNT to prevent metastasis: 24 Schröder et al. NEJM 2009; 360:1320 Schröder et al. NEJM 2009; 360:1320 ERSPC: Adjusting for compliance ERSPC: Update 21% risk reduction for cancer-specific mortality with screening (up to 38% in years 10-11) 29% risk reduction with adjustment for noncompliance Number needed to diagnose=33 Roobol et al. Eur Urol 2009; 56:584 Schröder et al. NEJM 2012; 366:981 6
7 The Göteborg trial (the best prostate cancer screening RCT you ve never heard of) Men (median 56) in a single Swedish city randomized without consent in 1994 to biannual screening until age 69 vs. no screening 9952 men in each arm Referral to urologist at PSA 3.4, later reduced to 2.9 then to 2.5 ng/ml. Biopsies used sextant template 76% of men in screening arm were screened at least once; 93% of men with elevated PSA had at least one biopsy The Göteborg randomized trial Hugosson J. Lancet Oncol 2010; 11:725 Hugosson J. Lancet Oncol 2010; 11:725 The Göteborg randomized trial The Göteborg randomized trial RR 0.56 ( , p=0.002) RR 0.56 ( , p=0.002) NNS: 293, NNT: 12 Hugosson J. Lancet Oncol 2010; 11:725 Hugosson J. Lancet Oncol 2010; 11:725 7
8 The Göteborg randomized trial Absolute vs. relative benefit? Göteborg vs. PLCO & ERSPC Younger mean age at start of screening Lower PSA threshold for referral Q2 year interval Higher rate of biopsy among those with high PSA Lower rate of pre- and intra-study PSA contamination Longer followup (though still relatively short) At 14 years followup not lifetime Hugosson J. Lancet Oncol 2010; 11:725 Carroll et al. J Clin Oncol 2011; 29:345 Short-term Perspective Distorts Harms as Well As Benefits Short-Term Long-Term Lives saved Overdiagnoses A guideline based on outcomes at 8 or 10 years is completely meaningless! 58% of screen detections ERSPC after 9 years 28% of screen detections US population over lifetime (annual screening) The harms of screening: overtreatment Overdiagnoses/Lives saved 48 7 Courtesy of Ruth Etzioni 8
9 Fair assessment of harms? Adequate evidence shows that up to 5 in 1000 men will die within 1 month of prostate cancer surgery and between 10 and 70 men will have serious complications but survive. Radiotherapy and surgery result in long-term adverse effects, including urinary incontinence and erectile dysfunction in at least 200 to 300 of 1000 men treated with these therapies. Radiotherapy is also associated with bowel dysfunction Moyer et al. Ann Intern Med, epub The real problem: overtreatment Treatment by risk and age Cooperberg et al. J Clin Oncol 2010; 28:1117 Bechis et al. J Clin Oncol 2011; 29:235 9
10 What do PCPs do? Do PCPs care about the USPSTF? Walter et al. JAMA 2006; 296:2336 Tasian et al. Urol Oncol 30:155, 2012 Do PCPs care about the USPSTF? So what now? Prasad et al. JAMA 307:1692,
11 One approach Establishing a baseline PSA at 60 predicts long-term prostate cancer mortality Analysis of 1167 samples from matched to Malmö registry data 11.4% diagnosed, 2.7% died of prostate cancer If PSA <1.0 at age 60, likelihood of prostate cancer death <0.3% 90% of prostate cancer deaths occurred in men with PSA >2.0 (top quartile) or we can screen smarter Vickers et al. BMJ 341, 2010 Rationale for earlier screening (AUA) An interesting perspective A baseline PSA level above the median for age 40 is a strong predictor of prostate cancer The age adjusted mortality rate for prostate cancer between ages 55 and 64 is significant. Such men may have been cured by earlier diagnosis and treatment Younger men are more likely to have curable cancer PSA is a more specific test for cancer in younger men Earlier and less frequent testing might reduce mortality and costs compared to annual testing beginning later Patients at risk for, but who do not have cancer may be candidates for chemoprevention Greene et al. J Urol 2009; 182:2232 What seems to be missing from most of the PSA discussion is that the majority of men will have a normal PSA value and they will be reassured A normal PSA level offers peace of mind, a valued commodity in a world that is frequently full of troubling news. Detsky et al. JAMA 307:1035,
12 Multivariable risk assessment Targeting the right populations CaPSURE Adv CAPRA Score Porten et al. J Urol 2010; 184:1931 Targeting the right populations CaPSURE SFGH Adv CAPRA Score Porten et al. J Urol 2010; 184:1931 Risk Assessment and Risk- Adapted Management Diagnosis Treatment 12
13 SPCG-4 trial: RP vs. WW PIVOT Trial 52 centers over 7 years screened 13,022 pts to find 5023 eligible and accrue 731 (14.5% of eligible, more likely Af-Am, low grade) Bill-Axelson et al. New Engl J Med 2011; 364:1708 Wilt T. AUA 2011 Plenary Presentation. PIVOT Trial PIVOT Trial Wilt T. AUA 2011 Plenary Presentation. Wilt T. AUA 2011 Plenary Presentation. 13
14 Prostate Cancer Risk Assessment The UCSF-CAPRA Variable Level Points Variable Level Points Goal: inform physician-patient decisions about optimal initial treatment approach and timing Active surveillance Early local therapy Multimodal therapy Systemic therapy PSA 6 0 T-stage T1/T2 0 Gleason (primary/ secondary) T3a % of biopsy <34% 0 cores >30 4 positive >34% 1 1-3/ /4-5 1 Age < /1-5 3 >50 1 Sum points from each variable for 0-10 score Cooperberg et al. J Urol 2005; 173:1938 CAPRA: Cancer-specific survival Surveillance: Recent Experiences HR C-index 1.39 ( ) = 0.80 # at risk Institution (PI) Total (n) Strict* (n) Median age Inclusion criteria Royal Marsden (Parker) Gleason 3+4, PSA 15 ng/ml, ct stage 2a, 50% of cores positive University of Miami (Soloway) Gleason 6, PSA 10 ng/ml, ct stage 2, 2 cores, 20% of any core positive Johns Hopkins (Carter) UCSF (Carroll) Gleason 3+3, PSAD 0.15 ng/ml/ml, ct stage 1, 2 cores positive, 50% of any core positive Gleason 3+3, PSA 10 ng/ml, ct stage 2, 33% of cores positive, 50% of any core positive University of Toronto (Klotz) Gleason 6, PSA 10 ng/ml (until Jan 2000, for men >70: Gleason 3+4, PSA 15 ng/ml) ERSPC sites (Schröder) Gleason 3+3, PSA 10 ng/ml, PSAD 0.2 ng/ml/ml, ct stage 1c-2, 2 cores positive Memorial-Sloan Kettering (Eastham) Gleason 3+3, PSA 10 ng/ml, ct stage 2a, 3 cores positive, 50% of any core positive TOTAL Cooperberg et al. JNCI 2009; 101:878 Cooperberg et al. J Clin Oncol 29:3669,
15 Surveillance: Recent Experiences Active Surveillance: UCSF Institution Median followup (months) Progress by grade / volume (%) Progress by PSA / PSA kinetics (%) Treatment without progression (%) OS (%) CSS (%) PFS (%) Royal Marsden University of Miami NR NR Johns Hopkins NR* UCSF / University of Toronto ERSPC sites 52 NR Memorial- Sloan Kettering We need better biomarkers, imaging tests, and psychosocial interventions n/a n/a n/a Cooperberg et al. J Clin Oncol 29:3669, 2012 Dall Era et al. Cancer 2008; 112:2664 So what explains this graph? Treatment Changes Explain Only a Fraction of the Mortality Decline 40% drop in age-adjusted prostate cancer mortality since early 1990s No treatment Treatment Cases diagnosed since 1975 Siegel et al. CA Cancer J Clin 2012; 62:10 Cancer, in press. Courtesy of Ruth Etzioni 15
16 Mortality Trends Suggest a Clear Role for PSA Screening What if we listened to the USPSTF? No treatment Treatment Treatment and screening ERSPC benefit Cases diagnosed since 1975 Cancer, in press. Courtesy of Ruth Etzioni A Decision Aid for the Task Force How to save the baby: screen smarter Start earlier (e.g., 40) Screen less frequently if baseline is low Focus on populations at highest risk Screen for high-risk prostate cancer, don t over-treat low-risk disease Embrace active surveillance Fix incentives Refer early and wisely Change nomenclature Continue to develop novel biomarkers 16
17 Conclusions Screening saves lives, period. The USPSTF analysis downplays benefits, overestimates harms, and is predicated on far too short of a time horizon. D is the wrong conclusion. Overtreatment is without question a major public health problem. But the answers lie in smarter screening and better treatment decisions, not in wholesale cessation of screening. Post-test? 1. I will not offer PSA screening to any men 2. I will only offer PSA screening to men who specifically ask for it 3. I will discuss screening with men with long life expectancy, and individualize the decision to screen 4. I will screen most men over 40 in good health 5. I am more confused than I was an hour ago! 0% 6% 70% 12% 12%
PSA-based Early Detection in the US:
PSA-based Early Detection in the US: What Went Wrong, and How to Screen Smarter Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops PAHO/WHO Consultation on
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationLocalized prostate cancer
Prostate Cancer 2014 Localized prostate cancer Progress toward personalized care Matthew R. Cooperberg, MD,MPH Departments of Urology and Epidemiology & Biostatistics UCSF Mini Medical School July 22,
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationProstate Cancer Who needs active surveillance?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms.
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationTranslating Evidence Into Policy The Case of Prostate Cancer Screening. Ruth Etzioni Fred Hutchinson Cancer Research Center
Translating Evidence Into Policy The Case of Prostate Cancer Screening Ruth Etzioni Fred Hutchinson Cancer Research Center Prostate Cancer Mortality in the US 2011 Prostate Cancer Mortality in the US 2011
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationSHARED DECISION MAKING FOR PROSTATE CANCER SCREENING
SHARED DECISION MAKING FOR PROSTATE CANCER SCREENING 16 TH A N N U A L M A S S A C H U S E T T S P R O S T A T E C A N C E R S Y M P O S I U M Mary McNaughton-Collins, MD, MPH Foundation Medical Director
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationCancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April Ruth Etzioni Fred Hutchinson Cancer Research Center
Cancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April 2018? Ruth Etzioni Fred Hutchinson Cancer Research Center Three thoughts to begin 1. Cancer screening is a good idea in principle Detect
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationPersonalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017
Personalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017 Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops Osher
More informationUSA Preventive Services Task Force PSA Screening Recommendations- May 2018
GPGU - NOTÍCIAS USA Preventive Services Task Force PSA Screening Recommendations- May 2018 Rationale Importance Prostate cancer is one of the most common types of cancer that affects men. In the United
More informationOverdiagnosis. Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin
Overdiagnosis Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin Screening for prostate cancer «Screening for prostate cancer has become the poster child of overdiagnosis
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationProstate Cancer Screening. Dickon Hayne University of Western Australia
Prostate Cancer Screening Dickon Hayne University of Western Australia JMG Wilson & G Junger, WHO, 1968 p26-27 In theory, therefore, screening is an admirable method of combating disease, since it should
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationProstate-Specific Antigen (PSA) Screening for Prostate Cancer
Medical Coverage Policy Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 0215 Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Related
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationProstate Cancer Screening & Treatment Updates. Daniel Gilbert, D.O. 4/2017
Prostate Cancer Screening & Treatment Updates Daniel Gilbert, D.O. 4/2017 1 www.drgilberturology.com Prostate Cancer Screening 2 Disclosures, Sponsors & Locations Nothing to disclose, No sponsors Hospital
More informationAn Approach Using PSA Levels of 1.5 ng/ml as the Cutoff for Prostate Cancer Screening in Primary Care.
Thomas Jefferson University Jefferson Digital Commons Department of Urology Faculty Papers Department of Urology 10-1-2016 An Approach Using PSA Levels of 1.5 ng/ml as the Cutoff for Prostate Cancer Screening
More informationResponse to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners
Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationPSA & Prostate Cancer Screening
PSA & Prostate Cancer Screening DR JONATHAN REES MD MRCS MRCGP When a thing ceases to be a subject of controversy, it ceases to be a subject of interest Do you think we should have a national screening
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationOtis W. Brawley, MD, MACP, FASCO, FACE
Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology, Medical Oncology, Medicine and Epidemiology Emory University Atlanta, Georgia
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationPSA & Prostate Cancer Screening
PSA & Prostate Cancer Screening DR JONATHAN REES MD MRCS MRCGP Do you think we should have a national screening programme for Prostate Cancer using PSA? YES it s an outrage, women have breast cancer screening
More informationScreening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014
Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014 Canadian Task Force on Preventive Health Care October 2014 Putting Prevention into Practice Canadian Task
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationStacy Loeb, MD Department of Urology New York University (NY, USA)
Practice-Changing Publications in Prostate Cancer: The Year in Review Stacy Loeb, MD Department of Urology New York University (NY, USA) Acknowledgement AUA Prostate Cancer Update Course William J Catalona,
More informationManaging Prostate Cancer in General Practice
Managing Prostate Cancer in General Practice Tuesday 18 th September 2018 Presenters: Prof Jon Emery Assoc Prof Declan Murphy The education has been developed in partnership with Cancer Council Victoria,
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationImpact of PSA Screening on Prostate Cancer Incidence and Mortality in the US
Impact of PSA Screening on Prostate Cancer Incidence and Mortality in the US Deaths per 100,000 Ruth Etzioni Fred Hutchinson Cancer Research Center JASP Symposium, Montreal 2006 Prostate Cancer Incidence
More informationReducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study
Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and
More informationAcknowledgments: Maureen Rice, Rachel Warren, Judy Brown, Meghan Kenny, Sharon Peck-Reid, Sarah Connor Gorber
Screening for prostate cancer with prostate specific antigen and treatment of early-stage or screen-detected prostate cancer: a systematic review of the clinical benefits and harms May 2014 Lesley Dunfield
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Expected population impacts of discontinued prostate-specific antigen screening Permalink https://escholarship.org/uc/item/5fd7z6j0 Journal
More informationDecision-Analytic Modeling of PSA Screening an ONCOTYROL Project
Decision-Analytic Modeling of PSA Screening an ONCOTYROL Project EUFEP, Baden, June 24-26, 2009 Uwe Siebert, MD, MPH, MSc, ScD Professor of Public Health (UMIT) Adjunct Professor of Health Policy and Management
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationProstate-Specific Antigen Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive Services Task Force
Clinical Review & Education JAMA US Preventive Services Task Force EVIDENCE REPORT Prostate-Specific Antigen Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive
More informationProstate Cancer Screening Clinical Practice Guideline. Approved by the National Guideline Directors November, 2015
Prostate Cancer Screening Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by
More informationHarms and Benefits of Prostate Cancer Screening. and Active Surveillance
Harms and Benefits of Prostate Cancer Screening and Active Surveillance Gunstige en ongunstige effecten van het vroeg opsporing van prostaat kanker en actief opwachten Tiago M. C. D. Marques Harms and
More informationPSA as a Screening Test - AGP' GP's Perspective
PSA as a Screening Test - AGP' GP's Perspective Chris Del Mar cdelmar@bond.edu.auedu au Member of the RACGP Red Book Committee Background: prostate cancer is serious 9 th ranked cause of disease burden
More informationProstate Cancer Active Surveillance: Rationale, Outcomes and Future Directions
Prostate Cancer Active Surveillance: Rationale, Outcomes and Future Directions Daniel W. Lin, MD Professor and Chief of Urologic Oncology Bridges Endowed Professorship of Prostate Cancer Research Department
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationTITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening
TITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening RUNNING HEAD: Patient Heterogeneity in Prostate Cancer Screening June 17, 2016 Daniel J. Underwood,
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationPROSTATE CANCER: HOW CAN SUCH A COMMON DISEASE BE SO CONTROVERSIAL
PROSTATE CANCER: HOW CAN SUCH A COMMON DISEASE BE SO CONTROVERSIAL Shahrokh F. Shariat, MD Professor of Urology, Medical University of Vienna, Vienna, AUT Adjunct Professor of Urology and Medical Oncology,
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More informationProstate Cancer Screening in Norway
Prostate Cancer Screening in Norway Dr Freddie Bray Cancer Registry of Norway, Oslo GEKID / EK NRW Symposium: The Role of Cancer Registries in Cancer Screening Programmes a European Perspective DGEpi Conference
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationU.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017)
1 U.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017) Alex Krist MD MPH Professor and Director of Research Department of Family Medicine and Population Health
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationClinical Policy Title: Prostate-specific antigen screening
Clinical Policy Title: Prostate-specific antigen screening Clinical Policy Number: 13.01.06 Effective Date: May 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: April 19, 2017 Next
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationOncology: Prostate/Testis/Penis/Urethra
Oncology: Prostate/Testis/Penis/Urethra Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates Bimal
More informationCancer Screening: Controversial Topics 10/27/17. Vijay Kudithipudi, MD Kettering Cancer Care Radiation Oncology
Cancer Screening: Controversial Topics 10/27/17 Vijay Kudithipudi, MD Kettering Cancer Care Radiation Oncology Meet the Radiation Oncologists E Ronald Hale, MD, MPH Matthew Knecht, MD Anthony Paravati,
More informationPresenter Disclosure Information
2 3:15pm Screening Seniors: the Good, the Bad and the Questionable Presenter Disclosure Information The following relationships exist related to this presentation: Katherine Galluzzi, DO, CMD, has no financial
More informationProstate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence
DOI:10.1093/jnci/dju010 First published online March 4, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. Commentary
More informationThe Role Primary Care has in Reducing Prostate Cancer Disparities
The Role Primary Care has in Reducing Prostate Cancer Disparities Paul Monk Associate Professor Clinical Division of Medical Oncology Ohio State University Prostate Cancer Disparity Does it exist? Prostate
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More information